Intellia Therapeutics, Inc.
NTLANASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $1.49B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $7.95$27.86
- Volume (live)
- -
- Avg. volume (3M)
- 5.36M
Intellia Therapeutics (NTLA) Stock Price & Financial Analysis
Intellia Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $10.98 - $11.97 |
|---|---|
| 52-Week High | $27.86 |
| 52-Week Low | $7.95 |
| Open | $11.41 |
| Volume (last close) | 3.65M |
| Average Volume (3M) | 5.36M |
| Revenue (TTM) | 59.51M |
|---|---|
| Net Income (TTM) | -399.98M |
| Free Cash Flow (TTM) | -348.69M |
| EPS (TTM) | −$3.40 |
| Profit Margin | -672.16% |
| Operating Margin | -711.66% |
| Return on Equity (ROE) | -54.96% |
| Debt to Equity | 0.10 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.49B |
|---|---|
| Shares Outstanding | 133.48M |
| Price to Sales (P/S) | 25.03 |
| Price to Book (P/B) | 2.05 |
| EV/EBITDA | -3.67 |
| 50-Day MA | $12.25 |
|---|---|
| 200-Day MA | $13.02 |
| 1-Year Change | −56.89% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Intellia Therapeutics at a Glance
As of the Oct 22, 2026 close, Intellia Therapeutics (NTLA) has a market capitalization of $1.49B. The stock trades at 25.0× sales. Over the trailing twelve months it lost $399.98M on revenue of $59.51M and burned $348.69M of free cash flow. Revenue grew 12.6% year over year.
As of its latest reported balance sheet, it holds $106.13M in cash and securities against $73.41M of debt, a net cash position of $32.72M.
Intellia Therapeutics does not currently pay a dividend.
The share price is down 56.9% over the past year. At $11.16 (the Oct 22, 2026 close) it sits within its 52-week range of $7.95 to $27.86, below its 200-day moving average of $13.02.
Based on 17 professional analyst ratings from the past 90 days, the consensus is Hold with an average price target of $19.50, 74.7% above the Oct 22, 2026 close.
Frequently Asked Questions About Intellia Therapeutics
What is the current stock price for NTLA?
As of the Oct 22, 2026 close, NTLA stock trades at $11.16. The 52-week range is $7.95–$27.86, with a day range of $10.98–$11.97.
What is the P/E ratio for NTLA?
The P/E ratio (Price-to-Earnings) for NTLA is shown in the Key Statistics section. This valuation metric helps compare Intellia Therapeutics, Inc. to industry peers.
Does NTLA pay dividends?
Intellia Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for NTLA?
Based on ratings from 17 professional analysts over the last 90 days, the consensus for NTLA is Hold. The average 12-month price target is $19.50, a 74.7% upside from the Oct 22, 2026 close of $11.16.
What is the market cap of NTLA?
As of the Oct 22, 2026 close, Intellia Therapeutics's market capitalization is $1.49B, classifying it as a small-cap company. Intellia Therapeutics operates in the Healthcare sector within the Biotechnology industry.